Trial Profile

A phase II, multi-centre study to evaluate the safety and efficacy of tetradecanoylphorbol acetate in patients with acute myelocytic leukemia and myelodysplastic syndrome

Status: Not yet recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 Jun 2017

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

31 May 2017 According to a Rich Pharmaceuticals media release, the company has filed its submission package to the Institutional Review Board (IRB) of Phramongkutklao Hospital in Bangkok.
31 May 2017 According to a Rich Pharmaceuticals media release, the company is preparing submission packages for the Hospital's Internal Review Board (IRB) and the Thailand Food and Drug Administration (FDA). This package is near completion and the Company plans to submit it shortly.
16 Feb 2016 According to Rich Pharmaceuticals media release, company is planning to enrol patients from the US and Thailand.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com